European Respiratory Society Annual Congress 2012

Abstract Number: 3480

Publication Number: P313

Abstract Group: 5.2. Monitoring Airway Disease

Keyword 1: Biomarkers Keyword 2: Asthma - diagnosis Keyword 3: COPD - diagnosis

Title: Classification ability of two electronic noses in asthma and COPD

Dr. Rosamaria 18911 Capuano capuano@ing.uniroma2.it ¹, Prof. Nadia 18912 Mores nmores@rm.unicatt.it MD ¹, Dr. Andrea 18913 Trové andreatrove@yahoo.it MD ², Dr. Francesco 18914 Macagno macagno@rm.unicatt.it MD ³, Dr. Leonello 18915 Fuso leofuso@rm.unicatt.it MD ³, Dr. Chiara 18936 Mondino chiwind@libero.it MD ⁴, Dr. Giuseppe 18925 Santini santinigiuseppe@libero.it ¹, Prof. Arnaldo 18964 D'Amico damico@eln.uniroma2.it ⁵, Dr. Marco 18951 Santonico santonico@ing.uniroma2.it ⁵, Dr. Giorgio 18962 Pennazza G.Pennazza@unicampus.it ⁶, Prof. Salvatore 24308 Valente svalente@rm.unicatt.it ³ and Prof. Paolo 18971 Montuschi pmontuschi@rm.unicatt.it MD ¹. ¹ Pharmacology, Catholic University of the Sacred Heart, Rome, Italy ; ² Medicine, Ospedale San Carlo di Nancy, IDI, Rome, Italy ; ³ Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy ; ⁴ Immunodermatology, IDI, Rome, Italy ; ⁵ Electronic Engineering, University of Rome Tor Vergata, Rome, Italy and ⁶ Engineering, University Campus Biomedico, Rome, Italy .

Body: We compared the classification ability of two e-noses based on different technologies in asthma and COPD. Ten patients with severe asthma (3/7, males/females, age 67± 2.4 yrs, FEV₁ 51.7 ± 7.8% pred, FVC 82.2 ± 7.6% pred, P<0.001; 9 non-smokers, 1 current smoker), 9 COPD patients (7/2, males/females, age 69 ± 3.4 yrs, FEV₁ 68.9 ± 5.1% pred, FVC 82.6 ± 5.3% pred, P<0.001; ex-smokers) and 6 healthy non-smokers (4/2, males/females, age 49 ± 6.7 yrs, FEV₁ 109.6 ± 3.6% pred, FVC 109.4 ± 4.4% pred) were studied in a cross-sectional pilot study. After 5 min of tidal breathing with volatile organic compound-free air, two breath samples were collected from each subject and immediately analyzed with Cyranose 320 (Smiths Detection, Pasadena, USA) and Ten 2010 (University of Rome Tor Vergata, Italy). Data were analyzed by partial least square discriminant analysis with leave-one-out cross-validation. E-noses were initially used for classifying healthy subjects and patients with pulmonary disease and, then, asthma and COPD patients. Classification capacity between patients with respiratory disease and healthy subjects was as follow: Cyranose 320, 88%; Ten 2010, 88%; e-nose combination, 92%. Classification rate between asthma and COPD patients was as follow: Cyranose 320, 92%; Ten 2010, 86%, e-nose combination, 94%. These preliminary results suggest that a combination of e-noses slightly increases classification capacity in patients with severe asthma and COPD.